Development of mRNA-Based Vaccination for BRCA1-Mutated Cancers v1

Title: A Phase I/II Clinical Trial of mRNA-Encoded BRCA1 Therapy in BRCA1-Mutated Cancers: Assessing Safety, Efficacy, and Tumor SuppressionBackground: BRCA1 mutations are associated with a significantly increased risk of developing breast, ovarian, and other cancers due to defective DNA repair mechanisms. Current treatments, including PARP inhibitors, have shown limited long-term success, necessitating novel approaches. mRNA-based therapies represent a promising new frontier in cancer treatment, leveraging the body’s cellular machinery to restore functional proteins and improve therapeutic outcomes.Objective: This study aims to evaluate the safety, efficacy, and optimal dosing of an mRNA-based therapy encoding the BRCA1 gene in patients with advanced BRCA1-mutated cancers, including breast, ovarian, and glioblastoma. The therapy is designed to restore BRCA1 function, improve DNA repair capacity, and reduce tumor progression.Methods: This is a randomized, open-label, Phase I/II clinical trial. Participants with confirmed germline or somatic BRCA1 mutations and advanced-stage cancers that have progressed despite standard treatments will be enrolled. The trial will compare the safety and efficacy of the mRNA BRCA1 therapy against standard-of-care treatments, such as chemotherapy and PARP inhibitors. Primary outcome measures include tumor response rate as assessed by RECIST criteria and DNA repair efficiency, while secondary outcomes include progression-free survival (PFS), overall survival (OS), and adverse events.Expected Outcomes: We hypothesize that mRNA-encoded BRCA1 therapy will restore DNA repair functionality in BRCA1-mutated cells, leading to enhanced genomic stability and improved response to cancer treatment, ultimately reducing tumor growth and progression. If successful, this approach could offer a novel therapeutic option for patients with BRCA1-mutated cancers.Conclusion: This trial represents a pioneering effort to explore the potential of mRNA-based gene therapy in cancer treatment, specifically targeting BRCA1 mutations. Positive outcomes from this study could revolutionize treatment strategies for hereditary cancers and other malignancies associated with BRCA1 mutations.